JBCHEPHARM
506943JB Chemicals & Pharmaceuticals Ltd (JBCPL) is a leading Indian pharmaceutical company engaged in the development, manufacture, and marketing of a broad portfolio spanning formulations, active pharmaceutical ingredients (APIs), and specialty products. Established in 1976 and headquartered in Mumbai, the company has built a strong presence in both domestic and international markets, exporting to over 40 countries. Its key therapy areas include gastrointestinal, cardiovascular, anti-infectives, and pain management, with flagship brands such as Rantac and Metrogyl driving significant revenues.
JB Chemicals & Pharmaceuticals Ltd
About
JB Chemicals & Pharmaceuticals Ltd (JBCPL) is a leading Indian pharmaceutical company engaged in the development, manufacture, and marketing of a broad portfolio spanning formulations, active pharmaceutical ingredients (APIs), and specialty products. Established in 1976 and headquartered in Mumbai, the company has built a strong presence in both domestic and international markets, exporting to over 40 countries. Its key therapy areas include gastrointestinal, cardiovascular, anti-infectives, and pain management, with flagship brands such as Rantac and Metrogyl driving significant revenues.
JBCPL operates state-of-the-art manufacturing facilities approved by major regulatory authorities, including the US FDA, MHRA (UK), TGA (Australia), and SAHPRA (South Africa). The company leverages continual investments in R&D and compliance to strengthen its pipeline, focusing on branded generics, specialty, and contract manufacturing partnerships.
Business Model & Strategy
JB Chemicals & Pharmaceuticals Ltd generates revenue primarily through the manufacture and sale of branded formulations and APIs. Domestically, the company has a robust distribution network reaching clinics, hospitals, and pharmacies. Internationally, it focuses on regulated and emerging markets via direct sales and third-party distributorships, with differentiated products compliant with global regulatory norms.
Strategic growth levers include expansion of its product portfolio in high-growth therapeutic segments, strategic acquisitions (e. g. , the acquisition of brands from Sanzyme in 2022), and a sharpened focus on India-centric business for higher margin generics.
The company actively invests in R&D to upgrade its formulation pipeline and foray into specialty generics, while also developing its contract manufacturing (CDMO/CMO) capabilities for global clientele.
Management Overview
11 MembersMr.Arun Duggal
Non-Executive - Independent Director-ChairpersonMr.Sumit Bose
Non-Executive - Independent DirectorMs.Padmini Khare Kaicker
Non-Executive - Independent DirectorMr.Ashwani Kumar Puri
Non-Executive - Independent DirectorMr.Gaurav Trehan
Non-Executive - Non Independent DirectorMr.Prashant Kumar
Non-Executive - Non Independent DirectorMr.Akshay Tanna
Non-Executive - Non Independent DirectorMr.Nikhil Ashokkumar Chopra
Executive Director-CEOMs.Richa Arora
Non - Executive Independent DirectorMr.Narayan Saraf
Chief Financial OfficerMr.Sandeep Phadnis
Company Secretary & Compliance OfficerAwards & Recognition
4 Awards- Named among India's Top 35 Pharma Companies by market presence (ET Healthworld, 2023)
- Recognition as Great Place To Work (India, 2024)
- Awarded CMO Leadership Award for Quality (2023, Life Science Leader)
- Consistent recognition for operational sustainability and environmental initiatives in annual ESG disclosures (2023-24)
Market Information
Company Timeline
48+ Years of Excellence | 9 Major Milestones
Company founded and began commercial operations
Commencement of international exports
Initial Public Offering (IPO) and stock exchange listing
Approval by US FDA for key manufacturing facilities
Launch of key cardiovascular products in India
Acquisition by KKR, a global investment firm, boosting strategic focus
Acquisition of Sanzyme’s branded formulation portfolio
Expansion of CDMO/CMO business vertical for regulated markets
Recognition for sustainability and workplace excellence; continued portfolio expansion
The Next Evolution
Contact Information
Registered Office
B Wing, Neelam Centre, 4th Floor, Hind Cycle Road Worli
Tel: 022-2439 5200 / 5500,
Fax: 022-24930534,
Email: investorelations@jbpharma.com; secretarial@jbpharma.com
Website: jbpharma.com
Registrars
Datamatics Business Solutions Ltd
Tel: 022 - 66712001-06
Corporate Actions
0No Data Found
₹38,663 Cr.
N/A
₹2,526 / 1,639
62.37
₹259.05
9.3
₹38.62
₹1.00
0.91 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 1,685 | 1,825 | 2,155 | 2,463 | 3,159 | 3,521 | 3,956 | 4,208 | 3,099 |
| Expenses | - | - | - | 1,398 | 1,467 | 1,558 | 1,959 | 2,604 | 2,770 | 3,069 | 3,228 | 2,392 |
| Profit | - | - | - | 194 | 272 | 449 | 386 | 410 | 553 | 660 | 709 | 507 |
| Tax | - | - | - | 93 | 77 | 148 | 119 | 145 | 199 | 228 | 243 | 174 |
| EPS | - | - | - | 24 | 34 | 58 | 50 | 53 | 36 | 42 | 45 | 6.35 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 1,791 | 1,814 | 2,238 | 2,607 | 3,554 | 3,994 | 4,274 | 4,969 | - |
| Equity And Liabilities | - | - | - | 1,791 | 1,814 | 2,238 | 2,607 | 3,554 | 3,994 | 4,274 | 4,969 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 05 Apr '19 | Mar 2020 17 Apr '20 | Mar 2021 16 Apr '21 | Mar 2022 19 Apr '22 | Mar 2023 20 Apr '23 | Mar 2024 19 Apr '24 | Mar 2025 21 Apr '25 | Mar 2026 16 Apr '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | 0.01% | - | - | - |
| Promoter And Promoter Group | - | - | - | 56.02% | 55.91% | 55.91% | 54.00% | 53.93% | 53.78% | 47.84% | 48.80% | - |
| Non Institutions | - | - | - | 22.82% | 22.35% | 23.38% | 19.89% | 18.36% | 16.78% | 15.14% | 13.48% | - |
| FII | - | - | - | - | - | - | - | 8.63% | 11.06% | 18.30% | 16.33% | - |
| DII | - | - | - | - | - | - | - | 19.08% | 18.38% | 18.72% | 21.38% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
JB Chemicals & Pharmaceuticals Ltd
JB Chemicals & Pharmaceuticals Ltd
JB Chemicals & Pharmaceuticals Ltd (JBCPL) is a leading Indian pharmaceutical company engaged in the development, manufacture, and marketing of a broad portfolio spanning formulations, active pharmaceutical ingredients (APIs), and specialty products. Established in 1976 and headquartered in Mumbai, the company has built a strong presence in both domestic and international markets, exporting to over 40 countries. Its key therapy areas include gastrointestinal, cardiovascular, anti-infectives, and pain management, with flagship brands such as Rantac and Metrogyl driving significant revenues.
JBCPL operates state-of-the-art manufacturing facilities approved by major regulatory authorities, including the US FDA, MHRA (UK), TGA (Australia), and SAHPRA (South Africa). The company leverages continual investments in R&D and compliance to strengthen its pipeline, focusing on branded generics, specialty, and contract manufacturing partnerships.
JB Chemicals & Pharmaceuticals Ltd generates revenue primarily through the manufacture and sale of branded formulations and APIs. Domestically, the company has a robust distribution network reaching clinics, hospitals, and pharmacies. Internationally, it focuses on regulated and emerging markets via direct sales and third-party distributorships, with differentiated products compliant with global regulatory norms.
Strategic growth levers include expansion of its product portfolio in high-growth therapeutic segments, strategic acquisitions (e. g. , the acquisition of brands from Sanzyme in 2022), and a sharpened focus on India-centric business for higher margin generics.
The company actively invests in R&D to upgrade its formulation pipeline and foray into specialty generics, while also developing its contract manufacturing (CDMO/CMO) capabilities for global clientele.
Named among India's Top 35 Pharma Companies by market presence (ET Healthworld, 2023)
Recognition as Great Place To Work (India, 2024)
Awarded CMO Leadership Award for Quality (2023, Life Science Leader)
Consistent recognition for operational sustainability and environmental initiatives in annual ESG disclosures (2023-24)
Company founded and began commercial operations
Commencement of international exports
Initial Public Offering (IPO) and stock exchange listing
Approval by US FDA for key manufacturing facilities
Launch of key cardiovascular products in India
Acquisition by KKR, a global investment firm, boosting strategic focus
Acquisition of Sanzyme’s branded formulation portfolio
Expansion of CDMO/CMO business vertical for regulated markets
Recognition for sustainability and workplace excellence; continued portfolio expansion
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon